NCT06139666
The Effect of Liposomal Bupivacaine Nerve Block (Exparel) in Rotator Cuff Surgery
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Sponsor changed: The Cooper Health System to Cooper Norcross Health Show 6 more changesShow less
- Study completion date changed from estimate of Jun 1, 2025 to Dec 24, 2025
- Eligibility criteria expanded, about 7 words
- Trial status changed: Unknown → Completed
- Final enrollment: 128 participants (planned 160)
- Secondary endpoints: details revised at 1 of 1 entry
- Publications: details revised at 5 of 6 entries
- Minor Changed Registry marked status Unknown; last known: Enrolling by Invitation
- Minor Trial status: Enrolling by Invitation to Unknownv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Use of pain medications
Timeframe: 2 week postoperative visit
Secondary (1)
Pain severity
Arms and interventions
Control- Bupivacaine AloneActive comparator
patients will receive a standard interscalene block with bupivacaine alone (25 cc of bupivacaine)
Study- ExparelExperimental
patients will receive an interscalene block with Exparel solution, which is an extended-release formulation of bupivacaine consisting of 10cc liposomal bupivacaine mixed with 15cc bupivacaine. This is approved and used at the study institution
Drugs: Exparel Injectable Solution, Bupivacaine Injectable Solution
Sites
1 site in 1 country
- Cooper University HospitalCamden, New Jersey, United States